Xeris Biopharma Holdings (STU:2B30) Asset Impairment Charge : €0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Xeris Biopharma Holdings Asset Impairment Charge?

Xeris Biopharma Holdings's Asset Impairment Charge for the three months ended in Mar. 2025 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

Xeris Biopharma Holdings Asset Impairment Charge Historical Data

The historical data trend for Xeris Biopharma Holdings's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Asset Impairment Charge Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

Xeris Biopharma Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Xeris Biopharma Holdings Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Xeris Biopharma Holdings Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (STU:2B30) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

XERS:USA 0A8E:UK 2B30:Germany

Address

1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings Headlines

No Headlines